{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:57:21Z","timestamp":1790737041989,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI14C2686"],"award-info":[{"award-number":["HI14C2686"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["10526"],"award-info":[{"award-number":["10526"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.numecd.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T08:15:48Z","timestamp":1726128948000},"page":"2623-2629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2911-4920","authenticated-orcid":false,"given":"Ji Woo","family":"Baek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-3136","authenticated-orcid":false,"given":"Yeun Soo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keum Ji","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Kimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Ha","family":"Jee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2024.09.001_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5152\/tjg.2018.17330","article-title":"Liver fibrosis","volume":"29","author":"Ayd\u0131n","year":"2018","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.numecd.2024.09.001_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1535370219898141","article-title":"Mechanisms of liver fibrosis and its role in liver cancer","volume":"245","author":"Dhar","year":"2020","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.numecd.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11894-022-00835-8","article-title":"Models to predict development or recurrence of hepatocellular carcinoma (HCC) in patients with advanced hepatic fibrosis","volume":"24","author":"Yilma","year":"2022","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.numecd.2024.09.001_bib5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm12010356","article-title":"Risk of liver fibrosis is associated with more severe strokes, increased complications with thrombolysis, and mortality","volume":"12","author":"Toh","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.numecd.2024.09.001_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2024.09.001_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.numecd.2024.09.001_bib10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/HEP.0000000000000410","article-title":"What is in a name? toward culturally sensitive nomenclature for liver disease in the east and west","volume":"78","author":"Kim","year":"2023","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.numecd.2024.09.001_bib11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.numecd.2024.09.001_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.934225","article-title":"Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis","volume":"13","author":"Wen","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2024.09.001_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.31083\/j.rcm2406157","article-title":"The transition of cardiovascular disease risks from NAFLD to MAFLD","volume":"24","author":"Yang","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.numecd.2024.09.001_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.09.001_bib16","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib17","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102292","article-title":"Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study","volume":"65","author":"Moon","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.numecd.2024.09.001_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ije\/dyx226","article-title":"Cohort profile: the Korean cancer prevention study-II (KCPS-II) Biobank","volume":"47","author":"Jee","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.numecd.2024.09.001_bib20","article-title":"Non\u2013laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2024.09.001_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut and liver"},{"key":"10.1016\/j.numecd.2024.09.001_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jhep.2016.11.002","article-title":"Response to: comment to \u201cEASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease\u201d","volume":"66","author":"Marchesini","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.09.001_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2024.09.001_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction associated steatotic liver disease\u00a0(MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib26","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.metabol.2015.09.017","article-title":"Non-alcoholic fatty liver disease and risk of cardiovascular disease","volume":"65","author":"Lonardo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2024.09.001_bib28","article-title":"Obesity, cardiovascular disease, and the promising role of semaglutide: insights from the SELECT trial","author":"Irfan","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.numecd.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1111\/jgh.15589","article-title":"Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease","volume":"36","author":"Tamaki","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244405","article-title":"Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease","volume":"14","author":"Semmler","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.numecd.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-7-40","article-title":"Meta-analyses of FibroTest diagnostic value in chronic liver disease","volume":"7","author":"Poynard","year":"2007","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.numecd.2024.09.001_bib32","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1373\/clinchem.2004.032227","article-title":"Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C","volume":"50","author":"Poynard","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2024.09.001_bib33","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.09.001_bib34","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.numecd.2023.11.011","article-title":"Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: a population-based cohort study","volume":"34","author":"Ciardullo","year":"2024","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5009\/gnl.2013.7.3.323","article-title":"Prediction of advanced fibrosis in nonalcoholic fatty liver disease: an enhanced model of BARD score","volume":"7","author":"Lee","year":"2013","journal-title":"Gut Liver"},{"key":"10.1016\/j.numecd.2024.09.001_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-230X-12-2","article-title":"Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population","volume":"12","author":"Sumida","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.numecd.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1478-3231.2007.01614.x","article-title":"Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis","volume":"28","author":"Miyaaki","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2024.09.001_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2024.09.001_bib40","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Off J Am Coll Gastroenter ACG"},{"key":"10.1016\/j.numecd.2024.09.001_bib41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J Hepatol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532400334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532400334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:26:33Z","timestamp":1778775993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947532400334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S093947532400334X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2024.09.001","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease, liver fibrosis and risk of cardiovascular disease: A prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}]}}